Aardvark Therapeutics Reveals Promising Preclinical Data for ARD-201

Aardvark Therapeutics, Inc. ( (AARD) ) has shared an announcement.

On August 12, 2025, Aardvark Therapeutics announced promising preclinical data for ARD-201, showing significant weight loss in obesity models. The data suggest ARD-201’s potential as a monotherapy and in combination with GLP-1RA therapy, with plans for two Phase 2 trials to explore its efficacy in preventing weight regain and enhancing weight loss. This development could impact the obesity treatment landscape by offering a new oral solution for weight maintenance.

The most recent analyst rating on (AARD) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.

Spark’s Take on AARD Stock

According to Spark, TipRanks’ AI Analyst, AARD is a Underperform.

Aardvark Therapeutics, Inc. faces severe financial challenges typical of early-stage pharmaceutical companies, with zero revenue and substantial operational losses. The lack of technical and valuation indicators further contributes to the high-risk profile.

To see Spark’s full report on AARD stock, click here.

More about Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Their lead compound, ARD-101, is in Phase 3 clinical development for hyperphagia associated with PWS, and they are also developing ARD-201 to address limitations of current GLP-1RA therapies for obesity.

Average Trading Volume: 51,761

Technical Sentiment Signal: Strong Buy

Current Market Cap: $241.9M

For an in-depth examination of AARD stock, go to TipRanks’ Overview page.